{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:33:01Z","timestamp":1791639181463,"version":"4.3.4"},"reference-count":72,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s398118","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:00:11Z","timestamp":1756281611000},"page":"921-933","source":"Crossref","is-referenced-by-count":8,"title":["The Role of CELMoD Agents in Multiple Myeloma"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1251-4649","authenticated-orcid":true,"given":"Niels","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":true,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3390\/cancers15102693","volume":"15","author":"Larocca","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1603","DOI":"10.1002\/cnr2.1603","volume":"5","author":"Crawford","year":"2022","journal-title":"Cancer Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1021\/acsmedchemlett.9b00425","volume":"10","author":"Chamberlain","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-0716-1665-9_15","volume":"2365","author":"Thompson","year":"2021","journal-title":"Methods Mol Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cbpa.2017.05.016","volume":"39","author":"Raina","year":"2017","journal-title":"Curr Opin Chem Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","volume":"86","author":"Zheng","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1083\/jcb.201709072","volume":"217","author":"Klaips","year":"2018","journal-title":"J Cell Biol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMe2307370","volume":"389","author":"Shortt","year":"2023","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-319-46503-6_12","volume":"83","author":"Nguyen","year":"2017","journal-title":"Subcell Biochem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1042\/BCJ20160762","volume":"474","author":"Collins","year":"2017","journal-title":"Biochem J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14789450.2022.2142564","volume":"19","author":"Richardson","year":"2022","journal-title":"Expert Rev Proteomics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.18632\/oncotarget.27973","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"ref23","unstructured":"Bristol Myers Squibb. A study to compare iberdomide maintenance versus lenalidomide maintenance therapy following autologous stem cell transplant in participants with newly diagnosed multiple myeloma. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05827016. Accessed February 14, 2025."},{"key":"ref24","unstructured":"Celgene. Open-label study comparing iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) (EXCALIBER-RRMM). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04975997. Accessed February 14, 2025."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2019-124298","volume":"134","author":"Lonial","year":"2019","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood-2019-126146","volume":"134","author":"Amatangelo","year":"2019","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2023-178912","volume":"142","author":"Amatangelo","year":"2023","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.xcrm.2024.101571","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell Rep Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-137710","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-137667","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood-2024-199016","volume":"144","author":"Amatangelo","year":"2024","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.1182\/blood-2022-157987","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S2152-2650(23)01793-7","volume":"23","author":"Aleman","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/HS9.0000000000000566","volume":"5","author":"Lonial","year":"2021","journal-title":"HemaSphere"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-137743","volume":"136","author":"van de Donk NWCJ","year":"2020","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1182\/blood-2022-158180","volume":"140","author":"Lonial","year":"2022","journal-title":"Blood"},{"key":"ref41","author":"Lonial"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S2152-2650(23)01608-7","volume":"23","author":"White","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S2152-2650(24)01896-2","volume":"24","author":"Sureda Balari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/S2152-2650(22)00609-7","volume":"22","author":"van de Donk N","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"TPS8069","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069","volume":"41","author":"Lonial","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2023-177564","volume":"142","author":"van de Donk","year":"2023","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/hem3.104","volume":"8","author":"Gay","year":"2024","journal-title":"HemaSphere"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/S2152-2650(23)01755-X","volume":"23","author":"Gay","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1182\/blood-2019-124338","volume":"134","author":"Lopez-Girona","year":"2019","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2023-187748","volume":"142","author":"Chen","year":"2023","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/blood-2023-189445","volume":"142","author":"Chiu","year":"2023","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2019-124345","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1200\/JCO.2024.42.16_suppl.7539","volume":"42","author":"Trudel","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2023-174443","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sandhu I, Hofmeister CC, et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial. Oral presentation at the 65th American Society of Hematology Annual Meeting; December 9-12, 2023; San Diego, CA, USA.","DOI":"10.1182\/blood-2023-174443"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2024-198408","volume":"144","author":"Sandhu","year":"2024","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2024-198403","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1016\/S2152-2650(23)00876-5","volume":"23","author":"Richardson","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1016\/S2152-2650(24)02291-2","volume":"24","author":"Dimopoulos","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"TPS8070","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8070","volume":"41","author":"Richardson","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref64","unstructured":"Bristol Myers Squibb. A study to evaluate mezigdomide, bortezomib and dexamethasone (MEZIVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) (SUCCESSOR-1). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05519085. Accessed May 14, 2025."},{"key":"ref65","unstructured":"Bristol Myers Squibb. A study to evaluate mezigdomide in combination with carfilzomib and dexamethasone (MeziKD) versus carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (SUCCESSOR-2). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05552976. Accessed May 14, 2025."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cancers16061166","volume":"16","author":"Hartley-Brown","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1016\/S2352-3026(22)00322-2","volume":"9","author":"Rodriguez-Otero","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"972021","DOI":"10.3389\/fimmu.2022.972021","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front Immunol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e99048","DOI":"10.1172\/jci.insight.99048","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"Perez-Diez","year":"2007","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","volume":"2","author":"Li","year":"2018","journal-title":"Blood Adv"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"}],"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/106244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/106244","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:00:13Z","timestamp":1756281613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-role-of-celmod-agents-in-multiple-myeloma-peer-reviewed-fulltext-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":72,"URL":"https:\/\/doi.org\/10.2147\/ott.s398118","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}